Table 1.
Demographic and baseline characteristics of participants.
| Characteristics | Treatment group | Total (n = 48) | |
|---|---|---|---|
| CBD (n = 24) | Placebo (n = 24) | ||
| Age, mean (SD), y | 46.6 (10.1) | 45.4 (12.0) | 46.0 (11.0) |
| Female sex, n (%) | 4 (16.7) | 5 (20.8) | 9 (18.8) |
| Weight, mean (SD), kg | 74.9 (11.8) | 78.7 (20.4) | 76.8 (16.6) |
| Body mass index, mean (SD), kg/m2 | 25.0 (3.3) | 26.3 (5.6) | 25.7 (4.6) |
| Time between study initiation and last cocaine use, mean (SD), days | 2.1 (1.5) | 3.8 (3.9) | 2.9 (3.1) |
| Frequency of cocaine use 2 weeks before study initiation, mean (SD), days | 7.5 (4.5) | 6.0 (3.9) | 6.8 (4.2) |
| SDS total score, mean (SD) | 11.1 (2.3) | 11.9 (2.7) | 11.5 (2.5) |
| SDS group, n (%) | |||
| Low (SDS < 10) | 6 (25.0) | 5 (20.8) | 11 (22.9) |
| High (SDS ≥ 10) | 18 (75.0) | 19 (79.2) | 37 (77.1) |
| Severity of Cocaine Use Disorder based on the SCID, n (%) | |||
| Severe | 22 (91.7) | 23 (95.8) | 45 (93.8) |
| Moderate | 2 (8.3) | 1 (4.2) | 3 (6.3) |
| Preferred route of cocaine administration, n (%) | |||
| Nasal | 5 (20.8) | 10 (41.7) | 15 (31.3) |
| Smoking | 15 (62.5) | 13 (54.2) | 28 (58.3) |
| Non-intravenous injection | 1 (4.2) | 0 (0.0) | 1 (2.1) |
| Intravenous | 3 (12.5) | 1 (4.2) | 4 (8.3) |
| Highest level of schooling completed, n (%) | |||
| Less than high school | 8 (33.3) | 6 (25.0) | 14 (29.2) |
| High school | 7 (29.2) | 10 (41.7) | 17 (35.4) |
| More than high school | 9 (37.5) | 8 (33.3) | 17 (35.4) |
| Ethnicity, n (%) | |||
| White | 20 (83.3) | 21 (87.5) | 41 (85.4) |
| Other | 4 (16.7) | 3 (12.5) | 7 (14.6) |
| Employment status, n (%) | |||
| Full time | 7 (29.2) | 11 (45.8) | 18 (37.5) |
| Part time | 5 (20.8) | 6 (25.0) | 11 (22.9) |
| Disability or employment insurance | 2 (8.3) | 4 (16.7) | 6 (12.5) |
| Social welfare | 7 (29.2) | 2 (8.3) | 9 (18.8) |
| Unstable condition | 3 (12.5) | 1 (4.2) | 4 (8.3) |
| Marital status, n (%) | |||
| Married or common-law couple | 0 (0.0) | 2 (8.3) | 2 (4.2) |
| Single | 24 (100.0) | 22 (91.7) | 46 (95.8) |
| Housing status, n (%) | |||
| Stable housing | 21 (87.5) | 22 (91.7) | 43 (89.6) |
| Homeless | 3 (12.5) | 2 (8.3) | 5 (10.4) |
| Current substance use disorder, n (%) | 8 (33.3) | 6 (25.0) | 14 (29.2) |
| Cannabis | 3 (12.5) | 3 (12.5) | 6 (12.5) |
| Alcohol | 4 (16.7) | 3 (12.5) | 7 (14.6) |
| Stimulant | 1 (4.2) | 0 (0.0) | 1 (2.1) |
| Other | 2 (8.3) | 0 (0.0) | 2 (4.2) |
| Current and past medical conditions, n (%) | |||
| Cardiovascular | 4 (16.7) | 5 (20.8) | 9 (18.8) |
| Respiratory | 6 (25.0) | 6 (25.0) | 12 (25.0) |
| Hepatobiliary | 6 (25.0) | 5 (20.8) | 11 (22.9) |
| Gastroentorological | 2 (8.3) | 6 (25.0) | 8 (16.7) |
| Genital | 4 (16.7) | 2 (8.3) | 6 (12.5) |
| Hematological | 0 (0.0) | 1 (4.2) | 1 (2.1) |
| Musculoskeletal | 7 (29.2) | 4 (16.7) | 11 (22.9) |
| Neurological | 7 (29.2) | 4 (16.7) | 11 (22.9) |
| Endocrine | 0 (0.0) | 3 (12.5) | 3 (6.3) |
| Immunological | 0 (0.0) | 1 (4.2) | 1 (2.1) |
| Dermatological | 5 (2.8) | 2 (8.3) | 7 (14.6) |
| Allergy | 6 (25.0) | 1 (4.2) | 7 (14.6) |
| Otorhinolaryngology | 6 (25.0) | 4 (16.7) | 10 (20.8) |
| Neoplasia | 0 (0.0) | 1 (4.2) | 1 (2.1) |
| Other | 6 (25.0) | 3 (12.5) | 9 (18.8) |
Modified with permission from Mongeau-Pérusse et al. [33].
CBD cannabidiol, n number of participants, SCID structured clinical interview for the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-V), SD standard deviation, SDS Severity of Dependence Scale.